Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent
- Monday, October 5, 2020, 7:01
- Finance
- Add a comment
DALLAS, Oct. 5, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of…
About the Author
adminasapcorp has written 41532 stories on this site.